Analytical Data
-
Gene name
ICAM-3/CD50
- Application
-
Alternative Names
CDW50; CD50; ICAM-R
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P32942
-
Expression Region
Gly259~Val491
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ICAM-3 (Intercellular Adhesion Molecule 3) and CD50 (also known as CD2LG or LFA-3) are critical adhesion molecules involved in the immune response, particularly in the interactions between leukocytes and endothelial cells. These proteins play significant roles in cell signaling and migration, influencing processes such as inflammation and immune regulation. Research has shown that ICAM-3 functions as a ligand for LFA-1, promoting leukocyte adhesion and traversal through endothelium during immune responses. Meanwhile, CD50 interacts with CD2 on T cells, facilitating T cell activation and enhancing immune responses. Given their importance in immune cell interactions, understanding the structure and function of these proteins is essential for developing targeted therapies in various immune-related disorders, including autoimmune diseases and cancer. Recombinant ICAM-3/CD50 proteins are generated to study their biochemical properties, signaling pathways, and potential therapeutic applications. The ability to produce these proteins in a laboratory setting allows researchers to explore their roles in immune modulation and to screen for inhibitors or agonists that could serve as novel treatments. Overall, the study of ICAM-3/CD50 recombinant proteins offers valuable insights into immune dynamics and could lead to advancements in immunotherapy and the treatment of immune-mediated diseases.
